This anti-diabetic drug used for weight loss has been approved by US FDA: When will India see its launch?

economictimes.indiatimes.com:

obstructive sleep apnea (OSA), the US Food and Drug Administration (FDA) has granted approval for Zepbound (Tirzepatide), a drug typically used to manage type 2 diabetes and aid in weight loss, to be used in the treatment of OSA in adults with obesity. This marks the first time an anti-diabetic medication has been approved for managing this serious sleep disorder.

ET Year-end Special Reads

It's all Gucci for Indians' luxury craving even as economy shows wrinkles

Investing in 2025: Will domestic funds continue to counter FPI sell-offs amid rising valuations?

2024 exposed the underbelly of India's Silicon Valley

OSA is a condition characterized by intermittent pauses in breathing during sleep, which often leads to disrupted rest and other health complications.
Current treatments for moderate to severe OSA generally involve the use of assistive breathing devices, such as CPAP and Bi-Pap machines, which help keep the airway open during sleep.

However, the new approval of Zepbound, developed by Eli Lilly, offers an alternative that targets both obesity and sleep apnea.

Zepbound sales likely in India from 2025

Eli Lilly has also announced plans to launch Zepbound under the brand name Mounjaro in India by 2025, following the completion of necessary regulatory approvals. While the price of the drug in India is still under consideration, the company emphasized that its pricing strategy will reflect the drug’s proven efficacy, which not only addresses type 2 diabetes but also aims to reduce the significant health and